Eskalith Cr Oral Tablet, Extended Release 450Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Eskalith CR: Oral tablet, extended release (450mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_3147.JPG
Lithium Carbonate 450mg ER Tab
West-Ward Pharmaceutical
Pill Identification: WW 277 
Drug Image file DrugItem_5115.JPG
Lithium Carbonate 450mg ER Tab
Roxane Laboratories Inc
Pill Identification: 54 346 
Drug Image file DrugItem_13306.JPG
Lithium Carbonate 450mg ER Tab
Major Pharmaceuticals Inc
Pill Identification: WW 277 
Drug Image file DrugItem_15678.JPG
Lithium Carbonate 450mg ER Tab
Glenmark Pharmaceuticals
Pill Identification: G  |  224
Drug Image file DrugItem_13997.JPG
Lithium Carbonate 450mg ER Tab
American Health Packaging
Pill Identification: WW 277 
Drug Image file DrugItem_15679.JPG
Lithium Carbonate 450mg ER Tab
American Health Packaging
Pill Identification: G  |  224
Drug Image file DrugItem_5060.JPG
Eskalith CR 450mg ER Tab
GlaxoSmithKline Pharmaceuticals
Pill Identification: SKF J10 
Drug Image file DrugItem_17611.JPG
Lithium Carbonate 450mg ER Tab
American Health Packaging
Pill Identification: 54 346 

What is this Medicine?

LITHIUM (LITH ee um) is used to prevent and treat the manic episodes caused by manic-depressive illness.

In-Depth Information

Eskalith CR 450mg Extended-Release Tablet

NDC: 000074010
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Mania, Bipolar Disorder

Sometimes used for but not FDA approved for the following conditions:
Neutropenia, SIADH, Chemotherapy-induced Neutropenia, Zidovudine-induced Neutropenia, Agitation

Storage Information
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Eskalith CR 450mg Extended-Release Tablet
Drug Image file DrugItem_5060.JPG
GlaxoSmithKline Pharmaceuticals
Pill Identification: SKF J10 
Shape: round
Color: yellow

Reported Side Effects for Eskalith CR 450mg Extended-Release Tablet

Glomerulonephritis Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Vomiting Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Convulsions Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Serotonin Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Kidney Failure Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Overactive Thyroid Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Protein In The Urine Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Neuroleptic Malignant Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Nephrotic Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Enlarged Thyroid Gland Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Diabetes Insipidus Incidence:
1.0-10.0%*
Severity: SEVERE
Onset: DELAYED
Underactive Thyroid Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Birth Defect Incidence:
4.0-12.0%*
Severity: SEVERE
Onset: DELAYED
Weight Gain Incidence:
>10.0%*
Severity: MILD
Onset: DELAYED
Decreased Memory Incidence:
>10.0%*
Severity: MODERATE
Onset: DELAYED
Excessive Thirst Incidence:
>10.0%*
Severity: MILD
Onset: EARLY
Drowsiness Incidence:
>10.0%*
Severity: MILD
Onset: EARLY
Shaking Incidence:
>10.0%*
Severity: MILD
Onset: EARLY
Dry Skin Incidence:
>10.0%*
Severity: MILD
Onset: DELAYED
High White Blood Cells Incidence:
>10.0%*
Severity: MILD
Onset: DELAYED
Inceased Urination Incidence:
>10.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Eskalith CR 450mg Extended-Release Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Major Lifestyle Interaction
Caffeine-containing Foods/Beverages and Eskalith CR 450mg Extended-Release Tablet(Lithium Carbonate)
Caffeine-containing Foods/Beverages and Lithium(Lithium Carbonate)
Caffeine may decrease the effectiveness of Lithium. It is advisable to limit your caffeine intake (including teas, coffees, colas and non-prescription or herbal medicines containing caffeine) while taking Lithium. Report any changes in mood or emotions to your health care provider.
Moderate Lifestyle Interaction
Alcohol and Eskalith CR 450mg Extended-Release Tablet(Lithium Carbonate)
Alcohol and Lithium(Lithium Carbonate)
In general, it is advisable to avoid Alcoholic drinks while you are taking Lithium. Alcohol can affect mood and may increase the risk of side effects from Lithium such as drowsiness. Do not drive or perform other tasks requiring mental alertness if you are drinking alcohol-containing beverages.
Moderate Lifestyle Interaction
Foods high in sodium and Eskalith CR 450mg Extended-Release Tablet(Lithium Carbonate)
Foods high in sodium and Lithium(Lithium Carbonate)
Changes in sodium (salt) intake could result in changes in the Lithium level. It is important to have a consistent dietary intake of salt, and to make sure you drink adequate fluids. Remember that some foods may be high in sodium, talk to your health care provider if you have any questions about your diet. Your prescriber may order blood tests to measure the level of Lithium and Sodium (salt) in your blood. When taking Lithium, contact your prescriber immediately if you become confused, extremely tired or drowsy, or have nausea/vomiting, muscle weakness, slurred speech, tremor, or loss of balance.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Eskalith CR

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5